Evidence map›Paper›PMID 33514588›Full record

ArticleDisease models & mechanisms2021

NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells.

Ralitsa R Madsen, James Longden, Rachel G Knox, Xavier Robin, Franziska Völlmy, Kenneth G Macleod, Larissa S Moniz, Neil O Carragher, Rune Linding, Bart Vanhaesebroeck and 1 more

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. PI3K inhibitors are finally coming of age.Nature reviews. Drug discovery · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Ralitsa R MadsenCentre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.ORCID 0000-0001-8844-5167
James LongdenBiotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Rachel G KnoxMetabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK.
Xavier RobinBiotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Franziska VöllmyBiotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Kenneth G MacleodEdinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK.
Larissa S MonizUniversity College London Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6BT, UK.
Neil O CarragherEdinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK.
Rune LindingBiotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Bart VanhaesebroeckUniversity College London Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6BT, UK.
Robert K SempleCentre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.ORCID 0000-0001-6539-3069
University of Copenhagen · DKLondon Cancer · GBUniversity of Cambridge · GBWestern General Hospital · GBThe Queen's Medical Research Institute · GB

Funding

Cancer Research UK 15965Cancer Research UK 25722Medical Research Council MC_UU_12012/5
6 · The paper itself

Abstract

Activating PIK3CA mutations are known 'drivers' of human cancer and developmental overgrowth syndromes. We recently demonstrated that the 'hotspot' PIK3CAH1047R variant exerts unexpected allele dose-dependent effects on stemness in human pluripotent stem cells (hPSCs). In this study, we combine high-depth transcriptomics, total proteomics and reverse-phase protein arrays to reveal potentially disease-related alterations in heterozygous cells, and to assess the contribution of activated TGFβ signalling to the stemness phenotype of homozygous PIK3CAH1047R cells. We demonstrate signalling rewiring as a function of oncogenic PI3K signalling strength, and provide experimental evidence that self-sustained stemness is causally related to enhanced autocrine NODAL/TGFβ signalling. A significant transcriptomic signature of TGFβ pathway activation in heterozygous PIK3CAH1047R was observed but was modest and was not associated with the stemness phenotype seen in homozygous mutants. Notably, the stemness gene expression in homozygous PIK3CAH1047R hPSCs was reversed by pharmacological inhibition of NODAL/TGFβ signalling, but not by pharmacological PI3Kα pathway inhibition. Altogether, this provides the first in-depth analysis of PI3K signalling in hPSCs and directly links strong PI3K activation to developmental NODAL/TGFβ signalling. This work illustrates the importance of allele dosage and expression when artificial systems are used to model human genetic disease caused by activating PIK3CA mutations. This article has an associated First Person interview with the first author of the paper.

Indexed as

Phosphatidylinositol 3-KinasesPluripotent Stem CellsClass I Phosphatidylinositol 3-KinasesHumansMutationSignal TransductionTransforming Growth Factor betaClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesTransforming Growth Factor betaPI3KPIK3CAPluripotent stem cellsStemness

Identifiers

PMID33514588
PMCPMC7969366
OpenAlexW3122895689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.